In both the U.S. and Canadian markets, dietary supplements fall under established regulatory frameworks. Products must comply ...

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...

The start of the Phase I trial for IDE034 triggers a milestone payment to Biocytogen, from which Ideaya acquired the program in 2024.

-- The unmet need and current treatment landscape for GA -- The mechanism of disease and role of C1q -- Vonaprument, Annexon's neuroprotective C1q inhibitor with the potential to be the first targeted ...

Aberrant complement activation can cause damage to newly formed fetal-derived structures and excessive inflammatory response at the feto-maternal interface, contributing to pregnancy-related ...

Aivoxx is planning to build a plant that will covert 250,000 metric tons per year of household waste into 32,000 metric tons of SAF. Graham leads Aviation Week's coverage of technology, focusing on ...

Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may outperform existing treatments from Apellis Pharmaceuticals and Astellas ...

At this year’s MD&M West show, Hohenstein Medical, a division of Hohenstein Laboratories and a GLP-certified provider of testing, research and certification services for medical devices, will be ...

Please provide your email address to receive an email when new articles are posted on . Pegcetacoplan reduced proteinuria in patients with rare complement-mediated glomerular diseases vs. placebo.

GUELPH, ON / ACCESS Newswire / January 5, 2026 / Zentek Ltd. (ZTEK)(TSXV:ZEN) is pleased to announce that its wholly-owned subsidiary, Albany Graphite Corp. ("AGC"), has received final, positive ...

GUELPH, ON / ACCESS Newswire / January 5, 2026 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSXV:ZEN) is pleased to announce that its wholly-owned subsidiary, Albany Graphite Corp. ("AGC"), ...